

# Joining the Dots: Tackling Pharmaceuticals in the Environment, Halting the Spread of Antimicrobial Resistance

Nina Renshaw, Secretary General  
30 January 2018, European Parliament

european public health alliance





## PHARMACEUTICALS IN THE ENVIRONMENT & AMR: A EUROPEAN & GLOBAL PROBLEM

- **OVER-CONSUMPTION OF ANTIMICROBIALS, ESP ANTIBIOTICS**
- **IRRESPONSIBLE DISPOSAL OF PHARMACEUTICALS, E.G.**
  - Households, health & care facilities
  - Run-offs from intensive farming
  - Industrial effluents
- **INADEQUATE SEWAGE / WASTEWATER TREATMENT**
- **POLLUTING SURFACE & GROUND WATERS, INCL. MAJOR TRANSNATIONAL RIVERS (E.G. RHINE, MEUSE), SOIL, CROPS**
- **NEGATIVE IMPACT ON WATER QUALITY, DRINKING WATER SUPPLY, AQUATIC LIFE , LOCAL ECOSYSTEMS**
- **FACILITATING SPREAD OF DRUG-RESISTANT BACTERIA**





# **ANTIMICROBIAL RESISTANCE (AMR)**


**DECLINING EFFECTIVENESS OF ANTIBIOTICS**

**RETURN TO THE 'DARK AGES' OF MEDICINE**

**'DO NOTHING' SCENARIO 2050:**

- **10 MILLION DEATHS PER YEAR GLOBALLY**
- **700,000 DEATHS PER YEAR IN EUROPE**
- **BIGGER KILLER THAN CANCER**
- **COSTING 2-3% OF GLOBAL GDP**










# ENVIRONMENTAL POLLUTION: THE FORGOTTEN DIMENSION OF AMR









*“This is a **supply chain problem** that pharmaceutical companies and their suppliers need to solve together.”*

AMR Review, 8 December 2015



Review on  
Antimicrobial  
Resistance

*Tackling drug-resistant infections globally*





# FINANCIAL TIMES


HOME WORLD UK COMPANIES MARKETS OPINION WORK & CAREERS LIFE & ARTS

Drugs research

+ Add to myFT

## Big pharma targets drug-resistant superbugs

Initiative focuses on sales incentives, effluent from antibiotics plants and overprescription



© FT





# AMR INDUSTRY ALLIANCE

**AS OF APRIL  
2016:**

**98 COMPANIES,  
11 INDUSTRY  
ASSOCIATIONS,  
IN 21  
COUNTRIES**

**BUT...WHO IS  
MISSING??**

 1. Work to reduce the development of antimicrobial resistance	 2. Invest in R&D that meets global public health needs with new innovative diagnostics and treatments	 3. Improve access to high-quality antibiotics and ensuring that new ones are available to all
 Support appropriate use and improved stewardship	 Invest in innovative antibiotics, vaccines, alternative technologies, and diagnostics	 Ensure affordable access to new and existing antibiotics
 Encourage infection control	 Support research in academia and Small and Medium Enterprises on new and re-purposed antibiotics	 Support programs to improve global access
 Support the one health approach and responsible use	 Support open collaboration between industry and public researchers	
	 Develop new valuation mechanisms and commercial models with payers and policy makers	



## 2018: TURNING POINT?

- **PUBLIC CONSULTATION EXPLORES LINK BETWEEN PIE & AMR**
- **COMPREHENSIVE STRATEGY ON PIE – IMPORTANCE OF POLICY COHERENCE**
- **IMPROVE AND IMPLEMENT EU AMR ACTION PLAN (2017): EP INI REPORT BY MEP KADENBACH (AT, S&D)**
- **MAINTAIN MOMENTUM TO TACKLE AMR (WHO, UNGA, G20, UK GOVT...)**
- **REVIEW OF WATER FRAMEWORK DIRECTIVE**

### Public consultation on pharmaceuticals in the environment

#### PAGE CONTENTS

About this consultation

Target group

Objective of the consultation

How to submit your response

View the questionnaire

Reference documents

Additional information

Related links

Contact

#### About this consultation

Consultation period 22 November 2017 - 21 February 2018

Policy areas Environment, Public health

Departments [Environment](#)

#### Target group

All citizens and organizations are welcome to contribute to this consultation.

#### Objective of the consultation


The consultation seeks views on possible actions to address the risks from pharmaceuticals in the environment.

To obtain views and information to support the development of the Commission's strategic approach to pharmaceuticals in the environment.





- **INITIATE A MULTI-STAKEHOLDER DIALOGUE: TACKLE PIE AND AMR SIMULTANEOUSLY. PROTECT ENVIRONMENT & PUBLIC HEALTH**
- **NEW EU LEGISLATION AND POLICY MEASURES TO ADDRESS PHARMACEUTICAL POLLUTION:**
  - **Targets for EU and Member States to reduce AMR prevalence**
  - **Clean production**
  - **Responsible consumption**
  - **Safe disposal**
  - **Monitoring and reporting in EU and globally**



- **JOINT CALL TO ACTION ON AMR – EU HEALTH POLICY PLATFORM**
- **SIGNED BY OVER 40 ORGANISATIONS**
  1. Involve civil society in AMR-One Health policymaking;
  2. Support the implementation of National Action Plans & allocate adequate EU funds
  3. **Address all aspects of the One Health approach, incl. environment**
  4. Improve and regularly update the data on AMR burden in Europe
  5. Analyse and benchmark collected data
  6. Make full use of EU legislative powers in AMR relevant sectors
  7. Nurture and actively involve healthcare professionals, including students
  8. Put into practice existing evidence and continue scientific research
  9. Adopt a “prevention is better than cure” approach
  10. Support and promote the use of rapid diagnostic tests (RDTs)
  11. Empower patients and raise public awareness.



[illegible]